Galera Therapeutics and Obsidian Therapeutics merger
US$414m equity value
Announced 14 Apr 2026 · NASDAQ: OBX
Advisers
Galera Therapeutics
Acquirer
- Financial adviser
- Legal adviser
- Fairness opinion
Other advisers
- Legal adviser
- Goodwin

Team: Bill Collins, Tevia Pollard, Gabriela Morales-Rivera, Andrea Akinbola, Timbre Griffin, Keerthi Adusumilli, Madeleine Popp, Claire Treesh, Haylee Brown, Erini Svokos, Katerina Stavrianidis, Steven Tjoe, Krupa Zachariah, Matthew Wetzel, Dustin Schaefer, Tim Worden, Lucy Sharples, Oliver Samuel Walker, Alexandra Denniston, Austin Fahnestock, Timothy Holahan, Brendan Lally-McGurl, Daniel Karelitz, Devan Greevy, Arman Oruc, Simone Waterbury, Jim Matarese, Jonathan Burr, Caroline Bullerjahn, John Barker
Sidley Austin
Team: Asher Rubin, John Butler, Istvan Hajdu, Alison Lehner, Amanda Chong Artese, Nikita Ponomarev, Emily Chazen, Brendan McCartney, Suzanna Lewis, Sonia Gupta Barros, Katie Klaben, Kayla M. West, Kendell Lee, Demetrius Watson, Tanvi Sharan, Andrea Reed, Vadim Brusser, Torrey Cope, Kevin Sforza, Christian Brause, Greg Featherman, Eric M. Grosshandler, Morgan Ross, Benjamin Nager, Zani Doumbia
- Target
- Obsidian Therapeutics
- Acquirer
- Galera Therapeutics
- Target based in
- United States
- Buyer based in
- United States
- Completed
- 3 Aug 2026
- Sector
- Biotech
- Tags
- Biotech, Cell Therapy, Oncology
In the league tables
- M&A financial advisers, 2026 to date Leerink Partners #27 · Lucid Capital Markets #100
- M&A financial advisers, completed, 2026 to date Leerink Partners #45 · Lucid Capital Markets #72
- M&A legal advisers, 2026 to date Goodwin #12 · Sidley Austin #13
- M&A legal advisers, completed, 2026 to date Sidley Austin #13 · Goodwin #17
- Fairness opinion providers, 2026 to date Lucid Capital Markets #32
Similar deals
- AstraZeneca acquisition of AbelZeta's 50% share of China development and commercialisation rights to C-CAR031 Jan 2026 · US$630m · Biotech
- Eli Lilly and Company acquisition of Kelonia Therapeutics Apr 2026 · US$7bn · Biotech
- Gilead Sciences acquisition of Arcellx Feb 2026 · US$7.8bn · Biotech
- Treeline Biosciences and Standard BioTools merger Jun 2026 · US$460m · Biotech
- Ipsen acquisition of Kartos Therapeutics Jun 2026 · US$450m · Biotech
Sources
- 14 Apr 2026 Press release (EX-99.1, exhibit), Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent sec.gov
- 15 Apr 2026 Goodwin Advises Obsidian Therapeutics on Merger With Galera Therapeutics and $350 Million Private Placement Financing goodwinlaw.com
- 21 Apr 2026 Sidley Represents Galera Therapeutics in Its Merger With Obsidian Therapeutics and US$350 Million Private Placement Financing sidley.com
- 2 Jul 2026 Definitive merger information statement (DEFM14C), Galera Therapeutics, Inc. sec.gov
- 3 Aug 2026 Press release (EX-99.1, exhibit), Obsidian Therapeutics Completes Closing of Transaction with Galera sec.gov